P04035 (HMDH_HUMAN) Homo sapiens (Human)
3-hydroxy-3-methylglutaryl-coenzyme A reductase UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
22 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG AND COA |
Heteromer | 4×COA; 4×MAH; 2×DTT; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×8HI; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×4HI; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH COMPACTIN (ALSO KNOWN AS MEVASTATI… |
Heteromer | 4×114; 2×ADP; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×3HI; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×9HI; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×6HI; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×SO4; 4×5HI; | ||||
Assess | ||||||
Substituted Pyrazoles as Hepatselective HMG-COA reductase inhibitors |
Heteromer | 4×SO4; 4×RIE; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN |
Heteromer | 5×ADP; 4×117; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ROSUVASTATIN (FORMALLY KNOWN AS ZD… |
Heteromer | 3×ADP; 4×FBI; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH SIMVASTATIN |
Heteromer | 5×ADP; 4×SIM; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors |
Heteromer | 4×882; | ||||
Assess | ||||||
Design and Synthesis of Pyrrole-based, Hepatoselective HMG-CoA Reductase Inhibitors |
Heteromer | 4×882; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG, COA, AND NADP+ |
Heteromer | 4×COA; 4×MAH; 4×NAP; | ||||
Assess | ||||||
Design and synthesis of novel, conformationally restricted HMG-COA reductase inhibitors | homo-4-mer | 4×SO4; 4×HR2; | ||||
Assess | ||||||
Thermodynamic and structure guided design of statin hmg-coa reductase inhibitors | homo-4-mer | 4×SO4; 4×7HI; | ||||
Assess | ||||||
Design and synthesis of novel, conformationally restricted HMG-COA reductase inhibitors | homo-4-mer | 4×SO4; 4×HR1; | ||||
Assess | ||||||
Hepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inh… | homo-4-mer | 4×RID; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH CERIVASTATIN | homo-4-mer | 6×ADP; 4×116; | ||||
Assess | ||||||
COMPLEX OF CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG-COA | homo-4-mer | 4×HMG; | ||||
Assess | ||||||
COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH FLUVASTATIN | homo-4-mer | 4×115; 3×ADP; | ||||
Assess |
2 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
1hw8.1.B | monomer | 0.88 | 99.78 | |||
Assess | ||||||
8djk.1.A | monomer | 0.70 | 5×Y01; | 97.18 | ||
Assess |
4 SWISS-MODEL models built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
---|---|---|---|---|---|---|
Isoform 2 | 1dq9.1.C | monomer | 0.80 | 99.75 | ||
Assess | ||||||
Isoform 2 | 8djk.1.A | monomer | 0.71 | 5×Y01; | 97.18 | |
Assess | ||||||
Isoform 3 | 1dq9.1.C | monomer | 0.88 | 99.78 | ||
Assess | ||||||
Isoform 3 | 8djk.1.A | monomer | 0.69 | 5×Y01; | 97.18 | |
Assess |